Direction of the Company
NapaJen Pharma is a clinical-stage, biopharmaceutical company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel therapeutics.
While nucleic acid-based drugs have demonstrated significant therapeutic potential, their efficient and targeted delivery has presented key challenges to drug developers. This is largely due to the high instability, low bioavailability and poor cellular uptake associated with oligonucleotides. NapaJen Pharma has developed a novel solution designed to overcome these delivery challenges. Our proprietary approach creates oligonucleotide therapeutics that bind directly to Dectin-1, a cell surface receptor expressed on antigen-presenting immune cells such as dendric cells or macrophages.
Furthermore, by leveraging our unique in-house platform technology, we can significantly reduce the time required for the identification of novel nucleic acid drug candidates.
Based on this unique delivery technology, NapaJen Pharma is enabling the development of its own internal drug candidates, as well as positioning itself as a partner-of-choice for biotechnology and pharmaceutical companies seeking to develop their own novel oligonucleotide therapeutics.